Recent News

and/or

19 News Items found

Feature

How a Chicken Helped Solve the Mystery of Cancer

When this feathered patient found her way into a New York laboratory in 1909, she changed the course of cancer science.

A barred Plymouth Rock hen

Science Byte

Blocking Enzymes That Signal DNA Damage Could Be a Treatment Strategy for Childhood Cancers

A new strategy for treating pediatric cancers involves preventing cells from repairing their own DNA.

Graphic of shattered, red, DNA double-helix

In the Lab

Mirror-Image Chemistry Enables New Approach for Targeting an “Undruggable” Cancer-Causing Protein

MSK chemists are focusing on developing small-molecule drugs to target KRas, an important cancer protein.

Left-handed and right-handed KRas molecules

In the Lab

New Study Shows How Wayward Chromosomes Get Back on Track

MSK researchers are learning how cells are able to recognize and correct errors that occur during cell division.

A cell in the process of dividing

In the Lab

Manipulating a Single Gene Turns Colorectal Cancer Cells Back to Normal

For the first time, scientists have shown that the gene APC, which is mutated in the vast majority of colorectal cancers, might be a promising target for future therapies.

Organoid cell structures fluorescing in blue, green, and purple.

In the Lab

Uncharted Waters: The Making of a New Cancer Drug

A team of scientists is combining sophisticated chemistry and experiments in zebrafish to develop a new cancer drug that shows early potential against melanoma and metastatic breast cancer.

Portrait of a live zebrafish with dark patterning around and above the eyes

In the Lab

Miniature Device Could Unlock the Promise of Some Kidney Cancer Drugs

Memorial Sloan Kettering scientists have engineered a tiny particle that could ferry drugs directly to the kidneys and prevent their uptake in other organs.

Proximal tubule of the kidney.

Decoder

What Are Exceptional Responders?

When a clinical trial of a new drug fails because most patients don’t respond, progress can still be made by analyzing the tumors of the rare patients who benefit.

Exceptional responders of new drugs in clinical trials.

In the Clinic

The Evolution of a Lifesaving Drug: A Scientist Reflects

Physician-scientist Charles Sawyers played a pivotal role in the development of Gleevec, one of the first successful targeted drugs for cancer.

Pictured: Charles Sawyers

Finding

Study Reveals How Some Breast Cancers Become Resistant to Targeted Drugs

A study of one patient’s disease has clarified why tumors stop responding to a class of experimental drugs called PI3K inhibitors.

(From left) MSK investigators Michael Berger, José Baselga, and Maurizio Scaltriti, and graduate student Pau Castel.